Frontlight ResearchEarly access
Familial hypercholesterolaemia trials in Hong Kong
2 of 3 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in Hong KongA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
- Where
- Hong Kong
- Age
- 18 years and over
- People
- 204 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07930507 - Phase 3Taking peopleStudy to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
- Where
- Hong Kong
- Age
- 6 years to 11 years
- People
- 60 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06597019